PMC10419265_01
"Bright" appearing perivascular tissue in the echocardiography around CAA. *LAD, left coronary artery; **PA, pulmonary artery; ***AO, aorta; arrow; "bright" appearing perivascular tissue.
fped-11-1210940-g001.jpg
PMC10419265_01_fped-11-1210940-g001.jpg
F1
Despite a rapid normalization of inflammatory parameters, a third infusion of infliximab (5 mg/kg/day) was administered 1 week later due to the development of giant coronary artery dimensions (LAD: 4.9 mm, Z-score: 11.1; RCA: 5.8 mm, Z-score: 15.5) and persistent perivascular brightness (Figure 1).
Time course of clinical Kawasaki disease (KD) signs and laboratory values in relation to the prescribed KD medications (ASA, prednisone, IVIG, infliximab) and days after disease onset. LMWH, low-molecular-weight heparin; ASA, acetylsalicylic acid; IVIG, immunoglobulin; CrP, C-reactive protein.
fped-11-1210940-g002.jpg
PMC10419265_01_fped-11-1210940-g002.jpg
F2